Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Autor: Leboulleux S; Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Litière S; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU-Leuven (KU), Leuven, Leuven, Belgium., Godbert Y; Department of Oncology and Department of Nuclear Medicine, Institut Bergonie, Bordeaux, France., Rodien P; Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital Center (CHU) d'Angers, Angers, France., Jarzab B; Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Salvatore D; Department of Public Health, Azienda Ospedaliera Universitaria 'Federico II', Napoli, Italy., Zanetta S; Department of Medical Oncology, Centre Georges-Francois-Leclerc, Dijon, France., Capdevila J; Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Bastholt L; Department of Oncology, Odense University Hospital, Odense, Denmark., De La Fouchardiere C; Department of Medical Oncology, Centre Leon Berard, Lyon, France., Lalami Y; Institut Jules Bordet/Hôpital Universitaire de Bruxelles (HUB), Anderlecht, Belgium., Bardet S; Department of Nuclear Medicine and Thyroid Unit, Centre Francois Baclesse, Caen, France., Cornélis F; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Dedecjus M; Maria Skłodowska Curie's National Institute of Oncology, National Research Institute, Warsaw, Poland., Links T; University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Sents W; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Schlumberger M; Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France., Locati DL; Head and Neck Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy., Newbold K; Head and Neck Unit, Royal Marsden Hospital Sutton Surrey, Surrey, United Kingdom.

Publikováno v: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jun 27; Vol. 15, pp. 1403687. Date of Electronic Publication: 2024 Jun 27 (Print Publication: 2024).

Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups.

Autor: Locati LD; Department of Internal Medicine and Therapeutics, Univeristy of Pavia, Pavia, Italy; Translational Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy. Electronic address: lauradeborah.locati@unipv.it., Colombo E; Head and Neck Medical Oncology Unit, IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Dedecjus M; Maria Sklodowska-Curie National Research Institute of Oncology, Department of Oncological Endocrinology and Nuclear Medicine, Warsaw, Poland., de la Fouchardière C; Department of Medical Oncology, Léon Bérard Center, Lyon, France., Sents W; EORTC Headquarters, Brussels, Belgium., Bongiovanni M; Cytopathology, Synlab SA, Lausanne, Switzerland., Netea-Maier R; Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, Netherlands.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Feb; Vol. 180, pp. 146-154. Date of Electronic Publication: 2022 Dec 11.

1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)

Autor: Newbold, K., Schoeffski, P., Hasan, B., Locati, L.D., Godbert, Y., de la Fouchardiere, C., Bastholt, L., Fassnacht, M., Reed, N., Lalami, Y., Chougnet, C., Schvartz, C., Kapiteijn, E., Schlumberger, M.J., Sents, W., Sauve, N., Leboulleux, S.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S1087-S1088

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Autor: D'Ambrosio L; Department of Oncology, University of Turin, Turin, Italy.; Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy., Touati N; European Organization for Research and Treatment of Cancer, Brussels, Belgium., Blay JY; Leon Berard Center and Claude Bernard Lyon I University, EURACAN, LYRICAN, Lyon, France., Grignani G; Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy., Flippot R; Department of Medicine, Gustave Roussy, Villejuif Cedex, France., Czarnecka AM; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland.; Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland., Piperno-Neumann S; Medical Oncology Department, Curie Institute, Paris, France., Martin-Broto J; Virgen del Rocio University Hospital, Institute of Biomedicine Research/CSIC/University of Seville, Seville, Spain., Sanfilippo R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Katz D; Oncology Department, Sharett Institute of Oncology, Hadassah-Hebrew University, Jerusalem, Israel., Duffaud F; Medical Oncology - University Hospital Timone, Aix-Marseille University, Marseille, France., Vincenzi B; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy., Stark DP; St James's Institute of Oncology, Leeds Institute of Cancer and Pathology, University of Leeds and Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom., Mazzeo F; Medical Oncology, Clinique Universitaire Saint-Luc, Woluwe-Saint-Lambert, Belgium., Tuchscherer A; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany., Chevreau C; Claudius Regaud Institute, University Cancer Institute of Toulouse, Toulouse, France., Sherriff J; Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom., Estival A; Catalan Institute of Oncology, Barcelona, Spain., Litière S; European Organization for Research and Treatment of Cancer, Brussels, Belgium., Sents W; European Organization for Research and Treatment of Cancer, Brussels, Belgium., Ray-Coquard I; Leon Berard Center and Claude Bernard Lyon I University, EURACAN, LYRICAN, Lyon, France., Tolomeo F; Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy., Le Cesne A; Department of Medicine, Gustave Roussy, Villejuif Cedex, France., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland.; Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland., Stacchiotti S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Kasper B; Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Gronchi A; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Publikováno v: Cancer [Cancer] 2020 Jun 01; Vol. 126 (11), pp. 2637-2647. Date of Electronic Publication: 2020 Mar 04.

Modulating cell stiffness for improved vascularization: leveraging the MIL-53(fe) for improved interaction of titanium implant and endothelial cell.

Autor: Wu, Jie^1,2 (AUTHOR), Liu, Leyi^1,2 (AUTHOR), Du, Weidong^1,2 (AUTHOR), Lu, Yunyang^1,2 (AUTHOR), Li, Runze^1,2 (AUTHOR), Wang, Chao^1,2 (AUTHOR), Xu, Duoling^1,2 (AUTHOR), Ku, Weili^1,2 (AUTHOR), Li, Shujun³ (AUTHOR), Hou, Wentao³ (AUTHOR), Yu, Dongsheng^1,2 (AUTHOR) yudsh@mail.sysu.edu.cn, Zhao, Wei^1,2 (AUTHOR) zhaowei3@mail.sysu.edu.cn

Publikováno v: Journal of Nanobiotechnology. 7/17/2024, Vol. 22 Issue 1, p1-24. 24p.